Drug Development
Howard A. Burris III, MD
Sarah Cannon Research Institute
Initiated one of the world's largest and most widely publicized investigational drug development programs
- Burris has more than 20 years of phase I clinical trial experience, with a focus on investigational agents in breast cancer.
- He is chief medical officer and executive director of Drug Development at the Sarah Cannon Research Institute, Nashville, Tennessee, and is a partner with Tennessee Oncology.
- Burris is a past member of the American Society of Clinical Oncology (ASCO) Board of Directors and currently serves as member and chair-elect of the ASCO Nominating Committee.
- He sits on the boards of directors for the Sarah Cannon Research Institute, Tennessee Oncology, and the Minnie Pearl Foundation.
- Burris is a fellow of the American College of Physicians and is the editor of The Oncology Report. He is an author and coauthor of more than 300 published manuscripts and book chapters.
